• About Us
    • Contact Us
    • Login
    • ObGFirst
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • COVID-19
About Us Contact Us Login ObGFirst
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • COVID-19
Grand Rounds

Does Iatrogenic Delivery for Fetal Growth Restriction Impact Child Neurodevelopmental or Educational Outcomes

image_pdfFavoriteLoadingFavorite

BACKGROUND AND PURPOSE:

  • Selvaratnam et al. (JAMA, 2021) examined the association between iatrogenic delivery for suspected FGR and childhood school outcomes

METHODS:

  • Retrospective whole-population cohort study (Between 2003 an 2013)
    • Deidentified birth data from the Victorian Perinatal Data Collection
    • Linked to developmental and educational outcomes
  • Population
    • Births at ≥32 weeks’ gestation
  • Exposures
    • Suspected FGR vs no suspected FGR
    • Presence vs absence of iatrogenic delivery for FGR (induction or cesarean)
    • Presence vs absence of small for gestational age (SGA) | Birth weight <3rd percentile
  • Study design
    • Infants’ birth data were linked to their developmental and educational test scores at preparatory school, and grades 3, 5, and 7
  • Primary outcomes
    • Being in the bottom 10th percentile on 2 or more (of 5) developmental domains at school entry
    • Being below the national minimum standard on 2 or more (of 5) educational domains in grades 3, 5, or 7

RESULTS:

  • 705,937 infants
    • Mean (SD) gestation at birth: 39.1 (1.5) weeks
    • Mean (SD) birth weight: 3426 (517) grams
    • Children with developmental results: 181,902 | Children with educational results: 425,717
  • Compared with infants who had severe SGA but were not suspected of having FGR, infants who had severe SGA and were delivered for suspected FGR were born earlier
    • SGA only: 39.4 weeks
    • SGA and suspected FGR delivery: 37.9 weeks
  • Infants with SGA and suspected FGR had significantly increased risk of poor developmental outcomes
    • At school entry
      • SGA only: 12.7%
      • SGA and suspected FGR delivery: 16.2%
      • Absolute difference 3.5% (95% CI, 0.5 to 6.5%)
      • Adjusted odds ratio (aOR) 1.36 (95% CI, 1.07 to 1.74)
    • At grades 3, 5, and 7 | For example, the following was found at grade 7
      • SGA: 10.5%
      • SGA and suspected FGR delivery: 13.4%
      • Absolute difference 2.9% (95% CI, 0.4 to 5.5)
      • aOR 1.33 (95% CI, 1.04 to 1.70)
  • Infants with normal growth who were delivered for suspected FGR were born earlier than infants with normal growth that did not have suspected FGR
    • Normal growth: 39.1 weeks
    • Normal growth and suspected FGR delivery: 38.0 weeks
    • However, no significant difference found for educational or developmental outcome
      • Normal growth: 8.1%
      • Normal growth and suspected FGR delivery: 8.6%
      • Absolute difference 0.5% (95% CI −1.1 to 2.0)
      • aOR 1.17 (95% CI 0.95 to 1.45)
  • Further analysis of the data based on gestational age at delivery or preeclampsia did not alter the results

CONCLUSION:

  • Iatrogenic delivery of infants with severe SGA and suspected FGR had poorer developmental and educational outcomes than infants with severe SGA who were not suspected of having FGR
  • When infants had normal growth, earlier delivery with suspected FGR was not associated with worse outcomes, compared to normal growth infants with no suspicion of FGR
  • Significant limitations include lack of information related to fetal biometry, including Doppler studies | BMI and maternal smoking were not recorded prior to 2009
  • The authors note that the outcomes were stratified by age and suggest that

A more plausible explanation for the poorer outcomes for infants with severe SGA who were iatrogenically delivered for suspected FGR is that iatrogenic prematurity was harmful. This work suggests there may be a need to both better time delivery for infants with severe SGA and to target early childhood interventions toward improving child neurocognitive development in this high-risk cohort 

Learn More – Primary Sources:

Association Between Iatrogenic Delivery for Suspected Fetal Growth Restriction and School Outcomes

Want to stay on top of key guidelines and research papers?

ObGFirst® – Try It Free! »

image_pdfFavoriteLoadingFavorite
< Previous
All Grand Rounds Posts
Next >

Related ObG Topics:

SMFM Recommendations: FGR Diagnosis and Management
Fetal Growth Restriction: Definition, Evaluation and Management
STRIDER RCT Results: Sildenafil for Fetal Growth Restriction
Does Magnesium Sulfate Provide Neuroprotection in Preterm Fetuses with Growth Restriction?
Cesarean or Vaginal Delivery for Preterm Fetal Growth Restriction?

Sections

  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • Grand Rounds
  • My Bookshelf
  • COVID-19

Are you an
ObG Insider?

Get specially curated clinical summaries delivered to your inbox every week for free

  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Already a Member of ObGFirst®?

Please log in to ObGFirst to access the 2T US Atlas

Password Trouble?

Not an ObGFirst® Member Yet?

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!
ObGFirst Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site